Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
'With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by this devastating disease,' said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce. 'Across the landscape, this is an incredibly important and exciting time for patients and families affected by neuropathic MPS diseases. Looking ahead, we remain focused on pursuing accelerated approval of TA-ERT and filing the BLA in the first half of 2026. We also plan to initiate a confirmatory study prior to potential accelerated approval of TA-ERT and enable expanded access programs to ensure that patients have access to therapy.'
Corporate Updates
TA-ERT for the Treatment of MPS IIIB. Spruce entered into an Asset Purchase Agreement under which the company acquired an exclusive worldwide license agreement for TA-ERT and other enzyme replacement therapy products. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. In March 2024, in a Type C meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval. The FDA also confirmed that the completed clinical and non-clinical studies of TA-ERT were sufficient for a BLA submission and provided guidance around key design elements of a confirmatory trial, which must be initiated prior to potential accelerated approval of TA-ERT. TA-ERT has received Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in the U.S. and EU. Spruce intends to submit the BLA of TA-ERT for the treatment of MPS IIIB in the first half of 2026.
Tildacerfont and Cortibon for the Treatment of Major Depressive Disorder (MDD). Spruce entered into a license, development and option agreement (the 'HMNC Agreement') with HMNC Holding GmbH ('HMNC'). Under the terms of the HMNC Agreement, HMNC will fund and conduct a Phase 2 proof-of-concept study of tildacerfont, a potent and highly selective, oral, small-molecule antagonist of the CRF 1 receptor, in patients with MDD who will be screened using Cortibon, HMNC's proprietary genetic test. HMNC has initiated the Phase 2 TAMARIND study, which will explore the efficacy of 400mg twice-daily tildacerfont versus placebo in improving depressive symptoms in MDD patients. Topline results from TAMARIND are anticipated in the first half of 2026.
First Quarter 2025 Financial Results
Cash and Cash Equivalents: Cash and cash equivalents as of March 31, 2025 were $25.6 million. Cash and cash equivalents are expected to allow the company to fund its current operating plan through the end of 2025.
Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025 were $10.8 million compared to $10.3 million for the same period in 2024. R&D expenses for the three months ended March 31, 2025 include $5.7 million in costs related to the acquisition of SPR202, an anti-corticotrophin releasing hormone monoclonal antibody for the treatment of congenital adrenal hyperplasia.
General and Administrative (G&A) Expenses: G&A expenses for the three months ended March 31, 2025 were $3.7 million compared to $4.3 million for the same period in 2024, primarily driven by a decrease in stock-based compensation expense.
Total Operating Expenses: Total operating expenses for the three months ended March 31, 2025 were $14.5 million compared to $14.6 million for the same period in 2024. Operating expenses include non-cash stock-based compensation expenses of $0.5 million for the three months ended March 31, 2025 compared to $1.6 million for the same period in 2024.
Net Loss: Net loss for the three months ended March 31, 2025 was $14.0 million compared to $11.6 million for the same period in 2024.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data; the anticipated timing and conduct of Spruce's confirmatory trial for TA-ERT; the timing and likelihood of regulatory filings and approvals for TA-ERT, including the anticipated BLA Submission of TA-ERT for MPS IIIB in the first half of 2026; Spruce's expectation that topline results from the TAMARIND study will be available in the first half of 2026; and Spruce's intended focus on serious diseases with significant unmet medical need and clear biology, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'anticipate', 'will', 'potential', 'intend', 'expect' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
March 31,
2025
2024
ASSETS
Current assets:
Cash and cash equivalents
$
25,615
$
38,753
Prepaid expenses
2,899
3,177
Other current assets
2,062
2,276
Total current assets
30,576
44,206
Right-of-use assets
869
934
Other assets
204
69
Total assets
$
31,649
$
45,209
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,879
$
1,295
Accrued expenses and other current liabilities
12,442
12,329
Term loan, current portion
1,345
1,622
Total current liabilities
15,666
15,246
Lease liabilities, net of current portion
659
736
Term loan, net of current portion
—
124
Other liabilities
—
282
Total liabilities
16,325
16,388
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024
—
—
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 42,231,285 shares issued and outstanding as of March 31, 2025 and December 31, 2024
4
4
Additional paid-in capital
279,629
279,085
Accumulated deficit
(264,309
)
(250,268
)
Total stockholders' equity
15,324
28,821
Total liabilities and stockholders' equity
$
31,649
$
45,209
Expand
SPRUCE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended March 31,
2025
2024
Collaboration revenue
$
—
$
2,002
Operating expenses:
Research and development
10,837
10,317
General and administrative
3,655
4,318
Total operating expenses
14,492
14,635
Loss from operations
(14,492
)
(12,633
)
Interest expense
(36
)
(97
)
Interest and other income, net
487
1,105
Net loss and comprehensive loss
(14,041
)
(11,625
)
Net loss per share, basic and diluted
$
(0.32
)
$
(0.28
)
Weighted-average shares of common stock outstanding, basic and diluted
43,944,946
41,096,231
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Walmart recalls shrimp possibly exposed to radioactive material
Walmart has recalled some shrimp products in 13 US states after one shipment of seafood tested positive for radioactive contamination. The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers. One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said. Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it. "The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund. The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious. It came from an Indonesian supplier that has since had multiple shipping containers denied entry to the US, the FDA said. One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium. The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said FDA officials.
Los Angeles Times
38 minutes ago
- Los Angeles Times
Don't eat these potentially radioactive shrimp, FDA warns
The U.S. Food and Drug Administration is warning people to avoid eating certain raw frozen shrimp sold in Walmart stores as the agency investigates possible contamination by Cesium-137, a radioactive isotope. U.S. Customs and Border Protection alerted the FDA to the detection of Cesium-137 in a single shipment of imported frozen shrimp from the Indonesia-based company PT. Bahari Makmur Sejati, which does business under the name BMS Foods. Officials have since detected the radioactive isotope at four ports across the nation: Los Angeles, Houston, Miami; and Savannah, Ga. The amount of Cesium-137 detected within the contaminated shipment would not pose an acute hazard to consumers. However, long-term consumption would pose an elevated risk of cancer. Bags of the frozen food product are sold under the brand name Great Value at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. All containers and products that tested positive or alerted for Cesium-137 have been denied entry into the country, according to an FDA announcement on Tuesday. Federal officials are coordinating with Indonesian seafood regulatory authorities to investigate the root cause of the contamination. There have not been any reports of contaminated shrimp in the freezer section or within the U.S. food supply chain, authorities said. Cesium-137 can be found in soil, food and air, according to the Environmental Protection Agency. It is produced by nuclear fission for use in medical gauges and devices, but can also be a byproduct of nuclear reactors and weapons testing, the agency said. Though bags of frozen shrimp haven't tested positive for Cesium-137, officials say the product may have been prepared, packed or held in unsanitary conditions. Walmart has received shipments of the frozen food that were imported after the date of the first detection, but those specific shipments did not alert for contamination, officials said. Shoppers who purchased the following products should not consume eat or serve the frozen shrimp, but instead throw it away, authorities say: The FDA is currently recommending that Walmart completely recall the item. BMS Foods is also no longer allowed to import the products into the U.S. until the company addresses any potential issues.
Yahoo
41 minutes ago
- Yahoo
Raw Shrimp Sold at Walmart Recalled for Possible Radioactivity
The recall comes after one lot of the shrimp was determined to have low levels of Cs-137, a radioactive isotope NEED TO KNOW Shrimp sold at Walmart is being recalled for possible radioactivity The recall comes after one lot of the shrimp, provided by an Indonesian supplier, was determined to have low levels of Cs-137, a radioactive isotope While the amount of Cs-137 present in the affected lot would not cause immediate harm, the FDA's primary concern is for prolonged, low-dose exposure, which could cause cancer Raw shrimp sold at Walmart is being recalled. The grocery store chain issued a recall of three lots of frozen raw shrimp, the U.S. Food and Drug Administration shared in an announcement. The recall comes after one lot of the shrimp, imported from an Indonesian supplier, was found to contain Cs-137, a radioactive isotope with a half life of about 30 years. The FDA is now working with businesses in the U.S. that sell or distribute products from the supplier, PT. Bahari Makmur Sejati (known through its business name, BMS Foods), who received items after the date Cs-137 was first detected. The recall extends to lots sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. While the levels of Cs-137 detected in the single lot of frozen raw shrimp are classified below the FDA's Derived Intervention Level — and thus is not immediately hazardous to those who consume it — the organization stated its primary concern is for repeated, low-dose exposure. Prolonged consumption of Cs-137 correlates with a higher risk of cancer, as it can damage DNA in living body cells. The recalled product is Walmart's Great Value brand frozen raw shrimp, with a best by date of 3/15/27. The recalled product will feature lot codes 8005540-1, 8005538-1 or 8005539-1. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. The FDA found BMS Foods to be in violation of the Federal Food, Drug, & Cosmetic Act, as the product appears to have been processed in unsanitary conditions. The supplier has been added to a new import alert for chemical contamination, so as to prevent further products from BMS Foods from entering U.S. commerce until necessary improvements have been made. An FDA investigation into the supplier is ongoing. Read the original article on People
